FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288434605> ?p ?o ?g. }

• W4288434605 endingPage "1317" @default.
• W4288434605 startingPage "1317" @default.
• W4288434605 abstract "Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration-approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or develop resistance to this regimen, highlighting the need for additional, potentially biomarker-driven therapeutic approaches for patients with recurrent MMRP EC.To assess the potential positive outcomes and safety of the combination of the polyadenosine diphosphate-ribose polymerase inhibitor talazoparib and the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in recurrent MMRP EC.This investigator-initiated, open-label, single-arm, 2-stage, phase 2 study nonrandomized controlled trial patients at 4 institutions in the US. Key eligibility criteria included measurable disease, unlimited prior therapies, and all endometrial cancer histologies.Talazoparib, 1 mg, orally, daily, and avelumab, 10 mg/kg, intravenously, every 2 weeks, were administered until disease progression or unacceptable toxic effects.Statistical considerations were developed for 2 coprimary objectives of objective response rate and rate of progression-free survival at 6 months, with a 2-stage design that allowed for early discontinuation for futility. Prespecified exploratory objectives included the association of immunogenomic features (determined by targeted-panel next-generation sequencing and immunohistochemistry) with activity.Thirty-five female patients (mean [SD] age, 67.9 [8.41] years) received protocol therapy; 9 (25.7%) derived clinical benefit after meeting at least 1 of the 2 coprimary end points. Four patients (11.4%) exhibited confirmed objective response rates (4 partial responses), and 8 (22.9%) survived progression free at 6 months. The most common grade 3 and 4 treatment-related toxic effects were anemia (16 [46%]), thrombocytopenia (10 [29%]), and neutropenia (4 [11%]); no patient discontinued receipt of therapy because of toxic effects. Tumors with homologous recombination repair alterations were associated with clinical benefit from treatment with avelumab and talazoparib. Tumor mutational burden, tumor-infiltrating lymphocytes, and PD-L1 status were not associated with clinical benefit.The results of this nonrandomized controlled trial suggest that treatment with avelumab and talazoparib demonstrated a favorable toxic effect profile and met the predetermined criteria to be considered worthy of further evaluation in MMRP EC. Immunogenomic profiling provided insights that may inform ongoing and future studies of polyadenosine diphosphate-ribose polymerase and PD-L1 inhibitor combinations in endometrial cancer.ClinicalTrials.gov Identifier: NCT02912572." @default.
• W4288434605 created "2022-07-29" @default.
• W4288434605 creator A5002442036 @default.
• W4288434605 creator A5002656220 @default.
• W4288434605 creator A5005249381 @default.
• W4288434605 creator A5005786694 @default.
• W4288434605 creator A5020540710 @default.
• W4288434605 creator A5025967071 @default.
• W4288434605 creator A5029031286 @default.
• W4288434605 creator A5030257115 @default.
• W4288434605 creator A5032378308 @default.
• W4288434605 creator A5037844254 @default.
• W4288434605 creator A5037937774 @default.
• W4288434605 creator A5046031005 @default.
• W4288434605 creator A5053431449 @default.
• W4288434605 creator A5058249824 @default.
• W4288434605 creator A5059752515 @default.
• W4288434605 creator A5060086956 @default.
• W4288434605 creator A5060953135 @default.
• W4288434605 creator A5062515397 @default.
• W4288434605 creator A5068473904 @default.
• W4288434605 creator A5073323475 @default.
• W4288434605 creator A5076246054 @default.
• W4288434605 creator A5085452611 @default.
• W4288434605 creator A5089158382 @default.
• W4288434605 creator A5089955620 @default.
• W4288434605 date "2022-09-01" @default.
• W4288434605 modified "2023-10-18" @default.
• W4288434605 title "Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer" @default.
• W4288434605 cites W2034930875 @default.
• W4288434605 cites W2137842694 @default.
• W4288434605 cites W2612419201 @default.
• W4288434605 cites W2789873158 @default.
• W4288434605 cites W2923110060 @default.
• W4288434605 cites W2970410478 @default.
• W4288434605 cites W2995651451 @default.
• W4288434605 cites W3043876358 @default.
• W4288434605 cites W3132948359 @default.
• W4288434605 cites W3208650040 @default.
• W4288434605 cites W3211398585 @default.
• W4288434605 doi "https://doi.org/10.1001/jamaoncol.2022.2181" @default.
• W4288434605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35900726" @default.
• W4288434605 hasPublicationYear "2022" @default.
• W4288434605 type Work @default.
• W4288434605 citedByCount "10" @default.
• W4288434605 countsByYear W42884346052022 @default.
• W4288434605 countsByYear W42884346052023 @default.
• W4288434605 crossrefType "journal-article" @default.
• W4288434605 hasAuthorship W4288434605A5002442036 @default.
• W4288434605 hasAuthorship W4288434605A5002656220 @default.
• W4288434605 hasAuthorship W4288434605A5005249381 @default.
• W4288434605 hasAuthorship W4288434605A5005786694 @default.
• W4288434605 hasAuthorship W4288434605A5020540710 @default.
• W4288434605 hasAuthorship W4288434605A5025967071 @default.
• W4288434605 hasAuthorship W4288434605A5029031286 @default.
• W4288434605 hasAuthorship W4288434605A5030257115 @default.
• W4288434605 hasAuthorship W4288434605A5032378308 @default.
• W4288434605 hasAuthorship W4288434605A5037844254 @default.
• W4288434605 hasAuthorship W4288434605A5037937774 @default.
• W4288434605 hasAuthorship W4288434605A5046031005 @default.
• W4288434605 hasAuthorship W4288434605A5053431449 @default.
• W4288434605 hasAuthorship W4288434605A5058249824 @default.
• W4288434605 hasAuthorship W4288434605A5059752515 @default.
• W4288434605 hasAuthorship W4288434605A5060086956 @default.
• W4288434605 hasAuthorship W4288434605A5060953135 @default.
• W4288434605 hasAuthorship W4288434605A5062515397 @default.
• W4288434605 hasAuthorship W4288434605A5068473904 @default.
• W4288434605 hasAuthorship W4288434605A5073323475 @default.
• W4288434605 hasAuthorship W4288434605A5076246054 @default.
• W4288434605 hasAuthorship W4288434605A5085452611 @default.
• W4288434605 hasAuthorship W4288434605A5089158382 @default.
• W4288434605 hasAuthorship W4288434605A5089955620 @default.
• W4288434605 hasBestOaLocation W42884346051 @default.
• W4288434605 hasConcept C121608353 @default.
• W4288434605 hasConcept C126322002 @default.
• W4288434605 hasConcept C143998085 @default.
• W4288434605 hasConcept C2777088508 @default.
• W4288434605 hasConcept C2777381376 @default.
• W4288434605 hasConcept C2777701055 @default.
• W4288434605 hasConcept C2780057760 @default.
• W4288434605 hasConcept C2781413609 @default.
• W4288434605 hasConcept C535046627 @default.
• W4288434605 hasConcept C71924100 @default.
• W4288434605 hasConceptScore W4288434605C121608353 @default.
• W4288434605 hasConceptScore W4288434605C126322002 @default.
• W4288434605 hasConceptScore W4288434605C143998085 @default.
• W4288434605 hasConceptScore W4288434605C2777088508 @default.
• W4288434605 hasConceptScore W4288434605C2777381376 @default.
• W4288434605 hasConceptScore W4288434605C2777701055 @default.
• W4288434605 hasConceptScore W4288434605C2780057760 @default.
• W4288434605 hasConceptScore W4288434605C2781413609 @default.
• W4288434605 hasConceptScore W4288434605C535046627 @default.
• W4288434605 hasConceptScore W4288434605C71924100 @default.
• W4288434605 hasIssue "9" @default.
• W4288434605 hasLocation W42884346051 @default.
• W4288434605 hasLocation W42884346052 @default.
• W4288434605 hasLocation W42884346053 @default.
• W4288434605 hasOpenAccess W4288434605 @default.

• next